CDKN2A and lung adenocarcinoma: Lastly, in patients with stage IV lung adenocarcinoma, those with CDKN2A deletions in the primary focus had shorter overall survival than those with CDKN2A deletions in the metastatic focus (median 37.35 months vs. 45.67), but the difference was not statistically significant (P = 0.838; Figure 5F).